Story perspectives
Promising Alzheimer’s Treatment XPro1595 Shows Phase 2 Success
10/1/2025
1 of 1
Story summary
- INmune Bio submitted MINDFuL phase 2 results on XPro1595 to npj Dementia.
- XPro1595 selectively neutralizes soluble TNF to reduce neuroinflammation.
- The trial enrolled 206 participants, with promise in the amyloid/high-inflammation subgroup.
- Texas Tech University Health Sciences Center (TTUHSC) found blood-brain barrier remains intact in Alzheimer’s models.
- New findings suggest Alzheimer’s may be metabolic, with fat in brain cells guiding treatments.
